Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study

• Published in: International journal of clinical oncology 2024, Vol.29 (1), p.55-63
• Main Authors: Kagawa, Hirokazu, Urabe, Fumihiko, Kiuchi, Yuria, Katsumi, Kota, Yamaguchi, Ryotaro, Suhara, Yushi, Yoshihara, Kentaro, Goto, Yuma, Sadakane, Ibuki, Yata, Yuji, Saito, Shun, Kurawaki, Shiro, Ajisaka, Shino, Miyajima, Keiichiro, Takahashi, Kazuhiro, Iwatani, Kosuke, Imai, Yu, Sakanaka, Keigo, Nakazono, Minoru, Kurauchi, Takashi, Kayano, Sotaro, Onuma, Hajime, Aikawa, Koichi, Yanagisawa, Takafumi, Tashiro, Kojiro, Tsuzuki, Shunsuke, Furuta, Akira, Miki, Jun, Kimura, Takahiro
• Format: Article
• Language: English
• Subjects: Cancer Research; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - pathology; Chemotherapy; Chemotherapy, Adjuvant - methods; Clinical trials; Humans; Immunotherapy; Medical prognosis; Medicine; Medicine & Public Health; Multivariate analysis; Nephroureterectomy - methods; Oncology; Original Article; Prognosis; Retrospective Studies; Risk factors; Surgical Oncology; Survival; Urinary Bladder Neoplasms - drug therapy; Urologic Neoplasms - drug therapy; Urologic Neoplasms - surgery; Urological cancer; Urothelial carcinoma
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-023-02424-9

Background Recent clinical trials have reported improved disease-free survival rates of patients with stage pT3–4/ypT2–4 or pN + upper tract urothelial carcinoma (UTUC) on adjuvant nivolumab therapy. However, the appropriateness of the patient selection criteria used in clinical practice remains uncertain. Methods We retrospectively analyzed 895 patients who underwent nephroureterectomy to treat UTUC. The patients were divided into two groups: grade pT3–4 and/or pN + without neoadjuvant chemotherapy (NAC) or grade ypT2–4 and/or ypN + on NAC (adjuvant immunotherapy candidates) and others (not candidates for adjuvant immunotherapy). Kaplan–Meier curves were drawn to assess the oncological outcomes, including recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). Cox proportional hazards models were used to identify significant prognostic factors for oncological outcomes. Results The Kaplan–Meier curves revealed notably inferior RFS, CSS, and OS of patients who were candidates for adjuvant immunotherapy. Multivariate analysis revealed that pathological T and N grade and lymphovascular invasion (LVI) status were independent risk factors for poor RFS, CSS, and OS. Conclusion In total, 44.8% of patients were candidates for adjuvant immunotherapy. In addition to pathological T and N status, LVI was a significant predictor of survival, and may thus play a pivotal role in the selection of patients eligible for adjuvant immunotherapy.